Want to see CASIF full AI Analyst Report?
Top Page
CASI Pharmaceuticals
(OTC:CASIF)
Select Model
Select Model
Rating:46Neutral
Price Target:
$0.12
▼(-9.23% Downside)
Action:Reiterated
Date:07/14/26
The score is primarily weighed down by weak financial performance, including multi-year revenue declines, very large operating/net losses, persistent cash burn, and the major balance-sheet red flag of negative equity with higher debt. Technicals provide some offset with improving short-term momentum (price above key short-term averages and positive MACD), but the longer-term trend remains unfavorable versus the 200-day average. Valuation is constrained by a negative P/E and lack of dividend yield data, offering limited support.
Positive Factors
China / Asia commercialization footprint
Having an established commercialization footprint focused on China and broader Asia provides structural market access and local regulatory experience. This supports longer-term product rollouts, reimbursements and partner distribution, increasing the potential to scale approved assets across large patient populations.
Negative Factors
Negative equity and rising leverage
Negative stockholders’ equity is a major structural weakness that sharply reduces financial flexibility and heightens refinancing and dilution risk. Rising debt alongside contracted assets limits the company’s ability to fund R&D or commercial investments internally and constrains strategic optionality over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
China / Asia commercialization footprint
Having an established commercialization footprint focused on China and broader Asia provides structural market access and local regulatory experience. This supports longer-term product rollouts, reimbursements and partner distribution, increasing the potential to scale approved assets across large patient populations.
Read all positive factors
CASI Pharmaceuticals (CASIF) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.65M
Dividend YieldN/A
Average Volume (3M)219.83K
Price to Earnings (P/E)―
Beta (1Y)1.18
Revenue Growth-27.42%
EPS Growth-6.12%
CountryUS
Employees214
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.86
Shares Outstanding20,555,874
10 Day Avg. Volume60,876
30 Day Avg. Volume219,829
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)-0.42
Price to Sales (P/S)0.76
P/FCF Ratio-0.76
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.41
Revenue Forecast (FY)N/A
CASI Pharmaceuticals Business Overview & Revenue Model
Company Description
CASI Pharmaceuticals, Inc. operates as a biopharmaceutical firm, focusing on the development and commercialization of therapeutic and pharmaceutical products across the People's Republic of China, the United States, and international territories. ...
How the Company Makes Money
CASI Pharmaceuticals makes money primarily by commercializing prescription drugs and, where applicable, leveraging licensing and collaboration arrangements tied to those products. Revenue is generated from product sales in the markets where CASI (...
CASI Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
16
Very Negative
| Breakdown | Dec 2025 | Mar 2025 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 20.71M | 28.54M | 33.88M | 43.11M | 30.17M |
| Gross Profit | 10.06M | 11.15M | 20.05M | 27.28M | 17.61M |
| EBITDA | -43.77M | -34.87M | -21.54M | -35.79M | -33.40M |
| Net Income | -48.06M | -39.26M | -26.94M | -41.01M | -36.65M |
Balance Sheet | |||||
| Total Assets | 25.65M | 53.67M | 75.27M | 96.23M | 138.30M |
| Cash, Cash Equivalents and Short-Term Investments | 5.63M | 16.09M | 30.77M | 51.34M | 48.57M |
| Total Debt | 27.49M | 22.14M | 21.24M | 1.34M | 4.33M |
| Total Liabilities | 62.93M | 51.82M | 51.10M | 29.30M | 30.34M |
| Stockholders Equity | -37.28M | 1.85M | 24.16M | 44.57M | 84.50M |
Cash Flow | |||||
| Free Cash Flow | -20.77M | -29.46M | -22.21M | -26.70M | -42.34M |
| Operating Cash Flow | -20.75M | -29.22M | -19.97M | -21.09M | -26.84M |
| Investing Cash Flow | 951.00K | 11.24M | -9.67M | 31.16M | -20.69M |
| Financing Cash Flow | 11.25M | 15.43M | -907.00K | -3.27M | 29.64M |
CASI Pharmaceuticals Technical Analysis
Negative
0.13
Price Trends
0.14
Negative
0.14
Negative
0.47
Negative
Market Momentum
>-0.01
Negative
47.15
Neutral
29.74
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CASIF, the sentiment is Negative. The current price of 0.13 is below the 20-day moving average (MA) of 0.13, below the 50-day MA of 0.14, and below the 200-day MA of 0.47, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 47.15 is Neutral, neither overbought nor oversold. The STOCH value of 29.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CASIF.
CASI Pharmaceuticals Risk Analysis
CASI Pharmaceuticals disclosed 49 risk factors in its most recent earnings report. CASI Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
CASI Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $8.52M | -0.25 | -238.69% | ― | ― | 88.43% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $2.65M | -0.05 | 203.92% | ― | -27.42% | -6.12% | |
45 Neutral | $11.14M | -0.03 | 3114.17% | ― | ― | 85.06% | |
43 Neutral | $4.35M | -1.28 | -35.38% | ― | ― | 85.52% | |
41 Neutral | $14.42M | -0.25 | -503.79% | ― | ― | 80.28% |
* Healthcare Sector Average
CASIF
CASI Pharmaceuticals
0.13
-2.34
-94.82%
MBRX
Moleculin Biotech
0.59
-14.33
-96.04%
MBIO
Mustang Bio
0.57
-1.12
-66.15%
GNPX
Genprex
3.95
-154.23
-97.50%
CNSP
CNS Pharmaceuticals
6.00
-0.07
-1.15%
SNTI
Senti Biosciences
0.44
-1.15
-72.58%
CASI Pharmaceuticals Corporate Events
CASI Pharmaceuticals Rescinds Evomela License Termination in Settlement With Acrotech
Jun 29, 2026
CASI Pharmaceuticals said on June 29, 2026 that it has reached a settlement with Acrotech Biopharma over an arbitration tied to Acrotech’s purported termination of a 2014 license granting CASI exclusive rights to commercialize Evomela® ...
CASI Pharmaceuticals Director Resigns but Stays On as Consultant
Jun 2, 2026
CASI Pharmaceuticals announced that director Dr. Barbara Krebs-Pohl, PhD, resigned from the company’s board effective May 31, 2026, with the company stating her departure was not due to any disagreement. Following her resignation, she has ag...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.